-
公开(公告)号：US20210263029A1
公开(公告)日：2021-08-26
申请号：US17254227
申请日：2019-05-29
发明人： Zimin Chen , Junhui Xiong , Weiling Xu , Zuxing Weng , Long Wang , Xiaohong Zheng , Xudong Sun , Shengxiang Ge
IPC分类号： G01N33/543 , G01N33/68 , G01N33/577 , G01N33/535 , G01N33/533 , G01N21/76
摘要： The invention provides a kit for full-range detection of C-reactive protein based on chemiluminescence immunoassay and a method for full-range detection of C-reactive protein. The kit comprises an R1 reagent, an M reagent, an R2 reagent, a pre-excitation solution and an excitation solution. The R1 reagent, that is a sample treatment solution, is a 0.5M citric acid solution (pH 3.0-3.5, which is adjusted by disodium hydrogen phosphate dodecahydrate). The present invention also provides a kit for full-range detection of C-reactive protein, which comprises a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, a sample treatment solution, a second antibody labeled with horseradish peroxidase (HRP) or alkaline phosphatase (AP), a color developing solution. The invention also provides a method for full-range detection of C-reactive protein using the kit. Both the first antibody and the second antibody are monoclonal antibodies that can specifically react with C-reactive protein.
-
公开(公告)号：US11543413B2
公开(公告)日：2023-01-03
申请号：US16768848
申请日：2018-11-30
发明人： Shunhua Wen , Liuwei Song , Zuxing Weng , Haijun Lin , Feihai Xu , Xudong Sun , Shengxiang Ge
IPC分类号： G01N33/576 , G01N33/543
摘要： A kit for quantitatively detecting HBsAg and a method for quantitatively detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.
-
公开(公告)号：US20200308233A1
公开(公告)日：2020-10-01
申请号：US16901410
申请日：2020-06-15
发明人： Shengxiang Ge , Tingdong Li , Lianzhi Jia , Yijian Li , Miaoge Xue , Yuanjun Zeng , Huirong Pan , Jun Zhang , Ningshao Xia
摘要： The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.
-
4.发明申请Method for In-Vitro Preparation of Double-Layered Virus-Like Particles of Rotavirus 有权轮状病毒双层病毒样颗粒体外制备方法公开(公告)号：US20150252334A1
公开(公告)日：2015-09-10
申请号：US14429586
申请日：2013-06-24
发明人： Shengxiang Ge , Tingdong Li , Qingshun Guo , Feihai Xu , Jun Zhang , Ningshao Xia
IPC分类号： C12N7/00
CPC分类号： C12N7/00 , A61K38/162 , A61K39/00 , C12N7/04 , C12N2720/12322 , C12N2720/12323 , C12N2720/12333 , C12N2720/12334 , C12N2720/12352
摘要： The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
摘要翻译： 本发明涉及一种体外制备轮状病毒双层病毒样颗粒的方法。 该方法包括以下步骤：从裂解上清液中纯化轮状病毒VP6蛋白，以及体外组装由VP2蛋白和VP6蛋白组成的双层病毒样颗粒，其中蛋白质和病毒样颗粒可用于预防或 减少轮状病毒感染引起的临床症状。
-
5.发明申请ANTI-HBC QUANTITATIVE DETECTION METHOD AND USES THEREOF IN MONITORING AND CONTROLLING DISEASE PROGRESSION OF CHRONIC HEPATITIS B PATIENT AND IN PREDICTING THERAPEUTIC EFFECT 有权抗HBC定量检测方法及其在监测和控制慢性乙型肝炎患者疾病进展和预防治疗效果方面的应用公开(公告)号：US20150118674A1
公开(公告)日：2015-04-30
申请号：US14373611
申请日：2013-01-17
发明人： Quan Yuan , Liuwei Song , Wenbin Zhou , Zuxing Weng , Feihai Xu , Shengxiang Ge , Jun Zhang , Ningshao Xia
IPC分类号： G01N33/569
CPC分类号： G01N33/56983 , G01N33/5762 , G01N2333/02 , G01N2469/20 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analogue anti-HBV drug), and thus guide the patients to reasonably choose drugs.
摘要翻译： 本发明涉及一种用于定量检测抗HBc的方法及其在监测慢性乙型肝炎患者疾病进展和预测治疗效果中的应用。 通过定量检测抗乙型肝炎核心蛋白（Anti-HBc）的抗体，能够监测慢性乙型肝炎患者的疾病进展，有效预测接受乙型肝炎病毒治疗的慢性乙型肝炎患者的治疗效果（特别是 基于干扰素的治疗和基于核苷/核苷酸类似物抗HBV药物的治疗），从而指导患者合理选择药物。
-
公开(公告)号：US10723767B2
公开(公告)日：2020-07-28
申请号：US15575140
申请日：2016-05-20
发明人： Shengxiang Ge , Tingdong Li , Lianzhi Jia , Yijian Li , Miaoge Xue , Yuanjun Zeng , Huirong Pan , Jun Zhang , Ningshao Xia
IPC分类号： C07K14/005 , C12N7/00 , A61K39/12 , A61K39/15 , A61P31/14 , A61P1/12 , A61P1/00 , A61P29/00 , A61K39/00
摘要： The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.
-
公开(公告)号：US09862933B2
公开(公告)日：2018-01-09
申请号：US14429586
申请日：2013-06-24
发明人： Shengxiang Ge , Tingdong Li , Qingshun Guo , Feihai Xu , Jun Zhang , Ningshao Xia
CPC分类号： C12N7/00 , A61K38/162 , A61K39/00 , C12N7/04 , C12N2720/12322 , C12N2720/12323 , C12N2720/12333 , C12N2720/12334 , C12N2720/12352
摘要： The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.
-
公开(公告)号：US11339194B2
公开(公告)日：2022-05-24
申请号：US16901410
申请日：2020-06-15
发明人： Shengxiang Ge , Tingdong Li , Lianzhi Jia , Yijian Li , Miaoge Xue , Yuanjun Zeng , Huirong Pan , Jun Zhang , Ningshao Xia
IPC分类号： C07K14/005 , A61K31/14 , A61P1/12 , A61K39/12 , A61K39/15 , A61P31/14 , A61P1/00 , A61P29/00 , C12N7/00 , A61K39/00
摘要： The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.
-
9.发明申请公开(公告)号：US20180326422A1
公开(公告)日：2018-11-15
申请号：US15774953
申请日：2016-10-25
申请人： Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. , BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY , Xiamen University
发明人： Xianbo Qiu , Xiangzhong Ye , Shengxiang Ge , Shiyin Zhang , Pengfei Gao , Shangzhi Ji , Yongliang Yang , Zixin Qiu , Ningshao Xia
CPC分类号： B01L7/52 , B01L2300/1805 , G01N21/64 , G01N21/6428 , G01N21/645 , G01N2021/6471 , G01N2201/08
摘要： The present invention relates to a detection mechanism for polymerase chain reaction and a polymerase chain reaction device, wherein the detection mechanism comprises at least one excitation module group, each of the excitation module groups comprising two excitation modules for providing excitation light with two wavelengths; an excitation optical fiber, connected to the excitation modules, the excitation optical fiber transmitting the excitation light to at least one reaction tube, each of the reaction tubes receiving excitation light with two wavelengths; a receiving optical fiber, for collecting and transmitting a fluorescent signal from the reaction tube; at least one receiving module group, connected to the receiving optical fiber, each of the receiving module groups comprising two receiving modules, to respectively receive the fluorescent signal of two wavelengths from the same said reaction tube, and convert the fluorescent signal into an electrical signal for output; the detection mechanism is configured to detect the reaction tube in a time division manner, and multiplex the receiving module group to obtain an output result.
-
10.发明授权公开(公告)号：US10309964B2
公开(公告)日：2019-06-04
申请号：US15549443
申请日：2016-01-26
申请人： XIAMEN UNIVERSITY
发明人： Shengxiang Ge , Jinjie Li , Xi Huang , Tingdong Li , Jun Zhang , Ningshao Xia
IPC分类号： A61K39/42 , G01N33/53 , G01N33/543 , G01N33/569
摘要： The invention belongs to the fields of medicine and immunology, particularly, the field of immunological diagnosis. In particular, the invention discloses a method for assessing whether a subject is at risk of developing human cytomegalovirus (HCMV) active infection and a kit therefore. The method comprises the steps of: (1) determining the level of an antibody against a HCMV protein in a body fluid sample from the subject; and (2) comparing the level with a predetermined reference value, wherein if the level is below the predetermined reference value, the subject is determined to be at risk of developing HCMV active infection. In addition, the invention also discloses a method for screening a candidate drug which is capable of improving the ability of a subject to resist human cytomegalovirus (HCMV) active infection, and a kit therefore.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.02 秒)
